NO20071050L - Rapamycin-polymorf II og anvendelser derav - Google Patents

Rapamycin-polymorf II og anvendelser derav

Info

Publication number
NO20071050L
NO20071050L NO20071050A NO20071050A NO20071050L NO 20071050 L NO20071050 L NO 20071050L NO 20071050 A NO20071050 A NO 20071050A NO 20071050 A NO20071050 A NO 20071050A NO 20071050 L NO20071050 L NO 20071050L
Authority
NO
Norway
Prior art keywords
rapamycin
polymorphic form
rapamycin polymorph
provides
polymorph
Prior art date
Application number
NO20071050A
Other languages
English (en)
Inventor
Mahdi Fawzi
Tianmin Zhu
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35431373&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20071050(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20071050L publication Critical patent/NO20071050L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer rapamycin-polymorf form II. Denne oppfinnelse tilveiebringer også fremgangsmåter for fremstilling av rapamycin-polymorf form II og farmasøytiske preparater innbefattende rapamycin-polymorf form II.
NO20071050A 2004-08-20 2007-02-23 Rapamycin-polymorf II og anvendelser derav NO20071050L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60309604P 2004-08-20 2004-08-20
PCT/US2005/029364 WO2006023627A1 (en) 2004-08-20 2005-08-18 Rapamycin polymorph ii and uses thereof

Publications (1)

Publication Number Publication Date
NO20071050L true NO20071050L (no) 2007-05-15

Family

ID=35431373

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071050A NO20071050L (no) 2004-08-20 2007-02-23 Rapamycin-polymorf II og anvendelser derav

Country Status (22)

Country Link
US (1) US7282505B2 (no)
EP (1) EP1781671A1 (no)
JP (1) JP2008510710A (no)
KR (1) KR20070051863A (no)
CN (1) CN101039948A (no)
AR (1) AR050374A1 (no)
AU (1) AU2005277407A1 (no)
BR (1) BRPI0514407A (no)
CA (1) CA2575887A1 (no)
CR (1) CR8929A (no)
EC (1) ECSP077268A (no)
GT (1) GT200500223A (no)
IL (1) IL181170A0 (no)
MX (1) MX2007002044A (no)
NO (1) NO20071050L (no)
PA (1) PA8642501A1 (no)
PE (1) PE20060649A1 (no)
RU (1) RU2007104518A (no)
SV (1) SV2006002201A (no)
TW (1) TW200608973A (no)
WO (1) WO2006023627A1 (no)
ZA (1) ZA200701453B (no)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003254168A1 (en) 2002-07-30 2004-02-16 Wyeth Parenteral formulations containing a rapamycin hydroxyester
JP2007505932A (ja) 2003-09-18 2007-03-15 マクサイト， インコーポレイテッド 経強膜送達
US7349971B2 (en) * 2004-02-05 2008-03-25 Scenera Technologies, Llc System for transmitting data utilizing multiple communication applications simultaneously in response to user request without specifying recipient's communication information
US8551512B2 (en) * 2004-03-22 2013-10-08 Advanced Cardiovascular Systems, Inc. Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS
WO2006086750A1 (en) 2005-02-09 2006-08-17 Macusight, Inc. Liquid formulations for treatment of diseases or conditions
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
US8492400B2 (en) 2006-02-09 2013-07-23 Santen Pharmaceutical Co., Ltd. Stable formulations, and methods of their preparation and use
CN101443004B (zh) 2006-03-23 2013-03-06 参天制药株式会社 用于与血管通透性有关的疾病或病症的制剂
BRPI0714945B8 (pt) * 2006-07-25 2021-05-25 Abbott Lab composições de análogo de rapamicina e processos para preparação de formas cristalinas de análogos de rapamicinas
US7820812B2 (en) 2006-07-25 2010-10-26 Abbott Laboratories Methods of manufacturing crystalline forms of rapamycin analogs
US7812032B2 (en) 2006-07-25 2010-10-12 Abbott Laboratories Crystalline forms of rapamycin analogs
US8486926B2 (en) * 2006-11-17 2013-07-16 Harbor Therapeutics, Inc. Steroid tetrol solid state forms
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US20080175887A1 (en) * 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
JP2008305262A (ja) * 2007-06-08 2008-12-18 Konica Minolta Business Technologies Inc サーバ及びシンクライアント環境でのプリンタ紹介方法
WO2010024898A2 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
PT2365802T (pt) 2008-11-11 2017-11-14 Univ Texas Microcápsulas de rapamicina e utilização para o tratamento de cancro
DE102008060549A1 (de) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
CN102282457A (zh) * 2009-01-21 2011-12-14 拜康有限公司 确定西罗莫司稳定性的方法和制备其稳定形式的工艺
EP2391401A2 (en) 2009-02-02 2011-12-07 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Crystalline drug-containing coatings
US20120252834A1 (en) * 2009-08-05 2012-10-04 The Government Of United States, As Represented By The Secretary Of The Army Novel use and method of rapamycin to treat toxic shock
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
WO2013072392A1 (en) 2011-11-15 2013-05-23 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Combination of a phosphoinositide 3-kinase inhibitor and a modulator of the janus kinase 2-signal transducer and activator of transcription 5 pathway
US20150224190A1 (en) 2012-07-06 2015-08-13 Mohamed Bentires-Alj Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the IL-8/CXCR interaction
WO2014160328A1 (en) 2013-03-13 2014-10-02 The Board Of Regents Of The University Of Texas System Mtor inhibitors for prevention of intestinal polyp growth
JP6529012B2 (ja) 2013-10-08 2019-06-12 エイアイ・セラピューティクス・インコーポレーテッド リンパ脈管筋腫症の処置のためのラパマイシン
AU2014373683B2 (en) 2013-12-31 2020-05-07 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
MX2016010373A (es) * 2014-02-11 2016-11-30 Lam Therapeutics Inc Rapamicina para el tratamiento de linfangioleiomiomatosis.
US10307371B2 (en) 2014-02-11 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
HUP1400075A2 (hu) 2014-02-14 2015-08-28 Druggability Technologies Ip Holdco Jersey Ltd Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
NZ724756A (en) 2014-04-04 2023-07-28 Ai Therapeutics Inc An inhalable rapamycin formulation for treating age-related conditions
AU2015330905B2 (en) 2014-10-07 2021-02-25 AI Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension
MA40910A (fr) 2014-11-07 2017-09-12 Civitas Therapeutics Inc Poudres de rapamycine pour administration pulmonaire
CN106478663A (zh) * 2015-08-26 2017-03-08 博瑞生物医药（苏州）股份有限公司 一种依维莫司的干燥方法
EP3848065B1 (en) 2017-05-15 2023-07-26 C. R. Bard, Inc. Medical device with drug-eluting coating and intermediate layer
CN109020995A (zh) * 2017-06-12 2018-12-18 鲁南制药集团股份有限公司 一种替西罗莫司的晶型物
JP7262581B2 (ja) 2018-11-14 2023-04-21 ルトニックス，インコーポレーテッド 改質されたデバイス表面に薬物溶出コーティングを有する医療用デバイス
JP7487228B2 (ja) 2019-04-08 2024-05-20 バード・ペリフェラル・バスキュラー・インコーポレーテッド 改質されたデバイス表面に薬物溶出コーティングを有する医療用デバイス

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
UA41884C2 (uk) * 1993-11-05 2001-10-15 Амерікан Хоум Продактс Корпорейшн Спосіб відокремлення рапаміцину від кислотних, основних та неполярних нейтральних домішок, присутніх в концентраті екстрактів ферментаційного бульйону або маточних розчинів

Also Published As

Publication number Publication date
CR8929A (es) 2007-08-28
CA2575887A1 (en) 2006-03-02
ECSP077268A (es) 2007-03-29
WO2006023627A1 (en) 2006-03-02
AR050374A1 (es) 2006-10-18
RU2007104518A (ru) 2008-09-27
PE20060649A1 (es) 2006-08-10
CN101039948A (zh) 2007-09-19
JP2008510710A (ja) 2008-04-10
WO2006023627A8 (en) 2006-11-30
AU2005277407A1 (en) 2006-03-02
PA8642501A1 (es) 2006-05-16
MX2007002044A (es) 2007-03-29
TW200608973A (en) 2006-03-16
US7282505B2 (en) 2007-10-16
US20060040971A1 (en) 2006-02-23
EP1781671A1 (en) 2007-05-09
BRPI0514407A (pt) 2008-06-10
SV2006002201A (es) 2006-05-09
GT200500223A (es) 2006-03-09
ZA200701453B (en) 2010-08-25
KR20070051863A (ko) 2007-05-18
IL181170A0 (en) 2007-07-04

Similar Documents

Publication Publication Date Title
TW200608973A (en) Rapamycin polymorph Ⅱ and uses thereof
MX2007005221A (es) Formas cristalinas de ascomicina y preparacion de ellas.
SE0301372D0 (sv) Novel compounds
WO2006050161A3 (en) Therapeutic furopyrimidines and thienopyrimidines
CY1112402T1 (el) Ενισχυτες υποδοχεων γλουταμικου
ATE528989T1 (de) Kristalline feste rasagilin-base
SE0301373D0 (sv) Novel compounds
EA200971051A1 (ru) Ингибиторы p70 s6 киназы
DK1695710T3 (da) Krystallinsk betad-form af ivabradinhydrochlorid, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende denne
MX2009000884A (es) Derivados de piridizinona.
WO2008005877A3 (en) Inhibitors of c-kit and uses thereof
WO2009146218A3 (en) Compounds including an anti-inflammatory pharmacore and methods of use
BRPI0818672A2 (pt) 2'-fluor-2'-desoxitetra-hidrouridinas como inibidores da citidina desaminase
DK3530673T3 (da) Humaniserede anti-beta7-antagonister og anvendelser deraf
ECSP045088A (es) Forma polimorfica de rimonabant, su procedimiento de preparacion y composiciones farmaceuticas que la contienen
UA86591C2 (ru) Пирролодигидроизохинолины как ингибиторы pde10, фармацевтическая композиция на их основе
DK2054418T3 (da) Dihydrothieno-pyrimidiner som AKT-proteinkinase-inhibitorer
NO20073725L (no) CCI-779-polymorf og dens anvendelse
WO2007064553A3 (en) Thiazole derivatives as cxcr3 receptor modulators
WO2007070433A3 (en) 2-arylthiazole derivatives as cxcr3 receptor modulators
MX2009004290A (es) Inhibidores de proteasas de catepsina.
TW200613308A (en) Cyclobutanetetracarboxylate compound and preparation method thereof
TNSN06321A1 (en) Beta-carbolines useful for treating inflammatory disease
TWI374886B (en) Processes for preparing intermediates of pemetrexed
PL1507531T3 (pl) Trwałe kompozycje farmaceutyczne desloratadyny

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application